A variety of other topical therapies have been assessed as treatment for actinic lesions, with varied success. These include Solaraze™ (3% diclofenac sodium in 2-5% hyaluronan gel) Curaderm (0-005% solasodine glycosides (BEC), 10% salicylic acid, 5% urea, 0-1% melaleuca oil, 0-05% linolenic acid in cetomacrogol-based cream) and the nucleoside tubercidin (7-deaza-adenosine).
Quality of evidence: IV
We found no systematic reviews for any of these three topical therapies. We found one RCT for Solaraze™, but only the abstract was accessible. Although complete and partial responses were reported, neither was defined; time of final assessment was also not defined.102 In an open-label study,103 the responses in 29 patients were graded on a seven-point scale, ranging from "complete response" to "much worse", 30 days after treatment. The parameters used to determine this response grading, the degree of change required to increase or decrease a grading, as well as location of lesions, were not specified. Clearance rates for 90-day treatment are also available from two placebo-controlled trials reported in the package insert for Solaraze, but details of the trials were unavailable to us.
A case series used tubercidin to treat five patients with facial and scalp AK lesions.104
A single open-label trial treated 56 AK lesions using Curaderm,105 with follow up at 3 months post-treatment.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.